Monitor for additional insider selling in coming weeks, isolated small sales by non-CFO/CFO-level executives are typically routine, but sustained selling could signal concern. No immediate trading signal.
KRYS drugs
KRYS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 27 $275.64entry
- T+1 · 9mo ago −6.11%α −6.16% · $258.81
- T+5 · 9mo ago −7.96%α −5.98% · $253.69
- T+20 · 8mo ago −10.97%α −3.42% · $245.39
- T+60 · 6mo ago +9.81%α +0.42% · $302.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Krystal Biotech CEO Krishnan Krish and Chief Accounting Officer Kathryn Romano sold shares in the open market, totaling $324,982 in proceeds over the past week. These were open-market sales by two executives, with the CEO selling 483 shares and the CAO selling 750 shares at prices between $257 and $268.
Key Financial Metrics
Key Facts
- CEO Krishnan Krish sold 483 shares at $257.31, totaling $124,282 in open-market transaction on March 4, 2026.
- Chief Accounting Officer Kathryn Romano sold 750 shares at $267.60, totaling $200,700 in open-market transaction on March 2, 2026.
- Total open-market sales by insiders in the past 7 days: $324,982.
- Sales represent approximately 0.0043% of Krystal Biotech's $7.6B market cap, well below the 0.1% threshold for materiality.
Financial Impact
$324,982 in total open-market sales by two executives; less than 0.01% of market cap
Risk Factors
- Perception of insider selling, even if immaterial, could weigh on sentiment if highlighted by retail investors.
- Future sales at higher volume or by additional C-suite members could indicate deeper concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-KRYS-1772839375312 |
Track record
18 reports on KRYS
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
- Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
- Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers